Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Urolithiasis
Published in: Urolithiasis 1/2016

01-02-2016 | Invited Review

Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Authors: Ammon B. Peck, Benjamin K. Canales, Cuong Q. Nguyen

Published in: Urolithiasis | Issue 1/2016

Login to get access

Abstract

Renal urolithiasis is a pathological condition common to a multitude of genetic, physiological and nutritional disorders, ranging from general hyperoxaluria to obesity. The concept of quickly dissolving renal uroliths via chemolysis, especially calcium-oxalate kidney stones, has long been a clinical goal, but yet to be achieved. Over the past 25 years, there has been a serious effort to examine the prospects of using plant and microbial oxalate-degrading enzymes known to catabolize oxalic acid and oxalate salts. While evidence is emerging that bacterial probiotics can reduce recurrent calcium-oxalate kidney stone disease by lowering systemic hyperoxaluria, the possible use of free oxalate-degrading enzyme therapy remains a challenge with several hurdles to overcome before reaching clinical practice.
Literature
1.
2.
Svedruzic D, Jonsson S, Toyota CG, Reinhardt LA, Ricagno S, Lindqvist Y, Richards NG (2005) The enzymes of oxalate metabolism: unexpected structures and mechanisms. Arch Biochem Biophys 433(1):176–192CrossRefPubMed
3.
Williams HE, Wandzilak TR (1989) Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 141(3 Pt 2):742–749PubMed
4.
Rodby RA, Tyszka TS, Williams JW (1991) Reversal of cardiac dysfunction secondary to type 1 primary hyperoxaluria after combined liver-kidney transplantation. Am J Med 90(4):498–504CrossRefPubMed
5.
Menon M, Mahle CJ (1982) Oxalate metabolism and renal calculi. J Urol 127(1):148–151PubMed
6.
Curhan GC, Willett WC, Rimm EB, Stampfer MJ (1993) A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328(12):833–838CrossRefPubMed
7.
Lindsjo M, Danielson BG, Fellstrom B, Ljunghall S (1989) Intestinal oxalate and calcium absorption in recurrent renal stone formers and healthy subjects. Scand J Urol Nephrol 23(1):55–59PubMed
8.
Bulgin MS (1988) Losses related to the ingestion of lincomycin-medicated feed in a range sheep flock. J Am Vet Med Assoc 192(8):1083–1086PubMed
9.
Costello JF, Smith M, Stolarski C, Sadovnic MJ (1992) Extrarenal clearance of oxalate increases with progression of renal failure in the rat. J Am Soc Nephrol 3(5):1098–1104PubMed
10.
Camici M, Balestri PL, Lupetti S, Colizzi V, Falcone G (1982) Urinary excretion of oxalate in renal failure. Nephron 30(3):269–270CrossRefPubMed
11.
Matthews LA, Doershuk CF, Stern RC, Resnick MI (1996) Urolithiasis and cystic fibrosis. J Urol 155(5):1563–1564CrossRefPubMed
12.
13.
Katz SM, Krueger LJ, Falkner B (1988) Microscopic nephrocalcinosis in cystic fibrosis. N Engl J Med 319(5):263–266CrossRefPubMed
14.
Hoppe B, Hesse A, Bromme S, Rietschel E, Michalk D (1998) Urinary excretion substances in patients with cystic fibrosis: risk of urolithiasis? Pediatr Nephrol 12(4):275–279CrossRefPubMed
15.
Hylander E, Jarnum S, Jensen HJ, Thale M (1978) Enteric hyperoxaluria: dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease. Scand J Gastroenterol 13(5):577–588CrossRefPubMed
16.
Lindsjo M, Danielson BG, Fellstrom B, Lithell H, Ljunghall S (1989) Intestinal absorption of oxalate and calcium in patients with jejunoileal bypass. Scand J Urol Nephrol 23(4):283–289CrossRefPubMed
17.
Stauffer JQ, Humphreys MH (1972) Hyperoxaluria with intestinal disease. N Engl J Med 287(8):412PubMed
18.
Worcester EM, Fellner SK, Nakagawa Y, Coe FL (1994) Effect of renal transplantation on serum oxalate and urinary oxalate excretion. Nephron 67(4):414–418CrossRefPubMed
19.
Dobbins JW, Binder HJ (1977) Importance of the colon in enteric hyperoxaluria. N Engl J Med 296(6):298–301CrossRefPubMed
20.
Allison MJ, Cook HM (1981) Oxalate degradation by microbes of the large bowel of herbivores: the effect of dietary oxalate. Science 212(4495):675–676CrossRefPubMed
21.
22.
23.
Hatch M, Freel RW, Vaziri ND (1994) Mechanisms of oxalate absorption and secretion across the rabbit distal colon. Pflugers Arch 426(1–2):101–109CrossRefPubMed
24.
Hatch M (1993) Oxalate status in stone-formers. Two distinct hyperoxaluric entities. Urol Res 21(1):55–59CrossRefPubMed
25.
Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV (1986) Oxalate degradation by gastrointestinal bacteria from humans. J Nutr 116(3):455–460PubMed
26.
27.
Kumar R, Ghoshal UC, Singh G, Mittal RD (2004) Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: possible role in renal stone formation. J Gastroenterol Hepatol 19(12):1403–1409CrossRefPubMed
28.
Goldfarb DS (2003) Increasing prevalence of kidney stones in the United States. Kidney Int 63(5):1951–1952CrossRefPubMed
29.
30.
Schissel BL, Johnson BK (2011) Renal stones: evolving epidemiology and management. Pediatr Emerg Care 27(7):676–681CrossRefPubMed
31.
Bihl G, Meyers A (2001) Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 358(9282):651–656CrossRefPubMed
32.
Khan SR, Hackett RL (1985) Calcium oxalate urolithiasis in the rat: is it a model for human stone disease? A review of recent literature. Scan Electron Microsc (Pt 2):759–774
33.
34.
de Bruijn WC, Boeve ER, van Run PR, van Miert PP, de Water R, Romijn JC, Verkoelen CF, Cao LC, Schroder FH (1995) Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc 9(1):103–114
35.
Argenzio RA, Liacos JA, Allison MJ (1988) Intestinal oxalate-degrading bacteria reduce oxalate absorption and toxicity in guinea pigs. J Nutr 118(6):787–792PubMed
36.
Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB (2001) Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol 166(4):1487–1491CrossRefPubMed
37.
Cornelius JG, Peck AB (2004) Colonization of the neonatal rat intestinal tract from environmental exposure to the anaerobic bacterium Oxalobacter formigenes. J Med Microbiol 53(Pt 3):249–254CrossRefPubMed
38.
Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, Peck AB (1999) Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10(Suppl 14):S334–S340PubMed
39.
Allison MJ, Dawson KA, Mayberry WR, Foss JG (1985) Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141(1):1–7CrossRefPubMed
40.
Allison MJ, MacGregor B, Sharp R, Stahl DA (2001) Genus Oxalobacter vol II. Bergey’s Manual of Systematic Bacteriology. Springer-Verlag, New York
41.
Sidhu H, Enatska L, Ogden S, Williams WN, Allison MJ, Peck AB (1997) Evaluating children in the Ukraine for colonization with the intestinal bacterium Oxalobacter formigenes, using a polymerase chain reaction-based detection system. Mol Diagn 2(2):89–97CrossRefPubMed
42.
Dawson KA, Allison MJ, Hartman PA (1980) Isolation and some characteristics of anaerobic oxalate-degrading bacteria from the rumen. Appl Environ Microbiol 40(4):833–839PubMedCentralPubMed
43.
Daniel SL, Hartman PA, Allison MJ (1987) Microbial degradation of oxalate in the gastrointestinal tracts of rats. Appl Environ Microbiol 53(8):1793–1797PubMedCentralPubMed
44.
Smith RL, Oremland RS (1983) Anaerobic oxalate degradation: widespread natural occurrence in aquatic sediments. Appl Environ Microbiol 46(1):106–113PubMedCentralPubMed
45.
46.
Sidhu H, Hoppe B, Hesse A, Tenbrock K, Bromme S, Rietschel E, Peck AB (1998) Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 352(9133):1026–1029CrossRefPubMed
47.
Nathanson S, Frere F, Tassin E, Foucaud P (2003) Urolithiasis in cystic fibrosis. Arch Pediatr 10(9):794–796CrossRefPubMed
48.
Bohles H, Michalk D (1982) Is there a risk for kidney stone formation in cystic fibrosis? Helv Paediatr Acta 37(3):267–272PubMed
49.
Sidhu H, Allison M, Peck AB (1997) Identification and classification of Oxalobacter formigenes strains by using oligonucleotide probes and primers. J Clin Microbiol 35(2):350–353PubMedCentralPubMed
50.
Binder HJ (1974) Intestinal oxalate absorption. Gastroenterology 67(3):441–446PubMed
51.
Moller T, Muller G, Schutte W, Rogos R, Schneider W (1987) Oxalic acid resorption in patients with resection of the small intestine, jejunoileal bypass, Crohn disease and chronic pancreatitis. Dtsch Z Verdau Stoffwechselkr 47(3):113–118PubMed
52.
Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, Gozzetti G, Miglioli M (1993) Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc 7(1):371–379 (discussion 379–380)
53.
McConnell N, Campbell S, Gillanders I, Rolton H, Danesh B (2002) Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 89(9):835–841CrossRefPubMed
54.
Trinchieri A, Lizzano R, Castelnuovo C, Zanetti G, Pisani E (2002) Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease. Arch Ital Urol Androl 74(2):61–64PubMed
55.
Worcester EM (2002) Stones from bowel disease. Endocrinol Metab Clin N Am 31(4):979–999CrossRef
56.
Canales BK, Hatch M (2014) Kidney stone incidence and metabolic urinary changes after modern bariatric surgery: review of clinical studies, experimental models, and prevention strategies. Surg Obes Relat Dis 10(4):734–742PubMedCentralCrossRefPubMed
57.
Jairath A, Parekh N, Otano N, Mishra S, Ganpule A, Sabnis R, Desai M (2015) Oxalobacter formigenes: opening the door to probiotic therapy for the treatment of hyperoxaluria. Scand J Urol 49(4):334–337PubMed
58.
Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D (2011) Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant 26(11):3609–3615CrossRefPubMed
59.
Mogna L, Pane M, Nicola S, Raiteri E (2014) Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? J Clin Gastroenterol 48(Suppl 1):S91–S95CrossRefPubMed
60.
Sinha M, Prabhu K, Venkatesh P, Krishnamoorthy V (2013) Results of urinary dissolution therapy for radiolucent calculi. Int Braz J Urol 39(1):103–107CrossRefPubMed
61.
Thalji NK, Richards NG, Peck AB, Canales BK (2011) Enzymatic dissolution of calcium and struvite crystals: in vitro evaluation of biochemical requirements. Urology 78(3):721.e713–721.e717
Metadata
Title
Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?
Authors
Ammon B. Peck
Benjamin K. Canales
Cuong Q. Nguyen
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Urolithiasis / Issue 1/2016
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-015-0845-6

Other articles of this Issue 1/2016

Urolithiasis 1/2016 Go to the issue

Invited Review

Can the manipulation of urinary pH by beverages assist with the prevention of stone recurrence?

Invited Review

Simplified methods for the evaluation of the risk of forming renal stones and the follow-up of stone-forming propensity during the preventive treatment of stone-formation

Invited Review

Preface

Invited Review

The management of patients with enteric hyperoxaluria

Invited Review

How should patients with cystine stone disease be evaluated and treated in the twenty-first century?

Invited Review

The exposome for kidney stones